ArticleScientific reports2026
Progressive cognitive impairment and ventricular tachycardia in a boy with biallelic POLG variants and a de novo RYR2 variation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Routine use of next-generation sequencing has shown that most common phenotypes are genetically heterogeneous and that in many cases, mutations in the same gene may cause markedly different phenotypes. Furthermore, complex clinical presentations are often due to multiple coexisting genetic defects. Here, we describe a patient with a complex clinical phenotype: a childhood-onset neurodevelopmental disorder with progressive intellectual disability, and supraventricular tachyarrhythmias that led to cardiac arrest in early teens. The complex phenotype is paralleled by a complex genotype. The neurological manifestations were likely due to biallelic POLG variants. POLG encodes the catalytic subunit of mitochondrial polymerase gamma. Pathogenic POLG variants cause both autosomal and recessive diseases, with a wide variety of clinical presentations. This heterogeneity makes validating novel substitutions challenging. One of the patient's variants, p.(W113R), was novel, and to assess its pathogenicity, we employed a functional yeast-based assay. The cardiac phenotype was likely due to a de novo pathogenic variant in the RYR2 gene, which encodes a calcium release channel that plays an essential role in heart excitation-contraction coupling. The yeast assay was essential to establish the pathogenicity of the novel POLG variant and to correctly characterize this complex genotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.